PSNL NASDAQ
Personalis, Inc.
1W: +0.2%
1M: -2.1%
3M: +36.2%
YTD: +103.6%
1Y: +65.1%
3Y: +1586.4%
5Y: -19.5%
$15.98
+0.10 (+0.63%)
After Hours: $15.72 (-0.26, -1.60%)
Weekly Expected Move ±2.0%
$15
$16
$16
$16
$16
Credit Risk of going bust: lower than 76% of companies Debt: 2.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Personalis, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $1.70B.
Distance to default 8.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $898K (short-term plus half of long-term), stock volatility 83.7%; Altman Z'' -2.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Personalis, Inc. would be worth roughly what it owes.
Total debt $38.0M against a stock market value of $1.70B.
Distance to default 8.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $898K (short-term plus half of long-term), stock volatility 83.7%; Altman Z'' -2.16. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Personalis, Inc. (NASDAQ:PSNL) Stock Rated “Hold” by Wall Street Analysts
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Personalis downgraded at BTIG on likely Tempus takeover
Aaron Tachibana Sells 2,931 Shares of Personalis (NASDAQ:PSNL) Stock
Stephen Michael Moore Sells 2,068 Shares of Personalis (NASDAQ:PSNL) Stock
Richard Chen Sells 3,998 Shares of Personalis (NASDAQ:PSNL) Stock
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 7,459 Shares
Tidal Investments LLC Buys New Shares in Personalis, Inc. $PSNL
Jupiter Topco LLC Buys New Position in Personalis, Inc. $PSNL
Personalis, Inc. $PSNL Shares Bought by Bank of America Corp DE
Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
Tempus AI upgraded at Piper Sandler on growth drivers
Personalis (NASDAQ:PSNL) Shares Gap Down Following Analyst Downgrade
Personalis falls amid a downgrade as a competitive bid appears unlikely
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant
TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial
What Personalis (PSNL)'s Rising Revenue But Deepening Losses Means For Shareholders - simplywall.st
Ameriprise Financial (PSNL) discloses 5.8% ownership stake in Personalis common stock - Stock Titan
Deep Track Capital (PSNL) reports 4,000,000 Personalis shares, now under 5% ownership - Stock Titan
Personalis (PSNL) Reports Higher Sales And Wider Losses, Does The Stock Look Fully Valued? - simplywall.st
Personalis (PSNL) Stock Commands A Premium Despite Deepening Losses - simplywall.st
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis Q2 revenue rises 30% to $22.4 million - Quiver Quantitative
Personalis Reports Second Quarter Results and Recent Highlights
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
BlackRock (PSNL holder) discloses 5.9% beneficial stake in Personalis common stock - Stock Titan
Tempus makes $1.5B bet to corner cancer-test market
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Sector Update: Healthcare Stocks Fall Late Afternoon
Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
TEM’s Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity – Retail Awaits To See Execution
Tempus to buy cancer test maker Personalis for $1.5B
Why is Personalis stock sliding today? By Investing.com - Investing.com Canada
Tempus AI to Acquire Personalis in $1.5 Billion Deal to Expand Precision Oncology Platform - Quiver Quantitative
Tempus AI : Acquisition of PSNL Investor Deck - marketscreener.com
Personalis (NASDAQ: PSNL) agrees to $1.5B Tempus AI stock-and-cash deal - Stock Titan
Tempus AI to Acquire Personalis in $1.5 Billion Deal
$Tempus AI (TEM.US)$ $Personalis (PSNL.US)$ - Moomoo
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal - Yahoo Finance
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders - Business Wire
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses.
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses. - Investor's Business Daily
PSNL Maintained by Needham -- Price Target Raised to $17 - GuruFocus
Personalis is said to have attracted takeover interest from Merck
Personalis is said to have attracted takeover interest from Merck - Seeking Alpha
Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $11.67
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Is PSNL Stock Up 5% After-Hours?
Personalis (PSNL) Recovers After Sale Speculation - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Insider Sale: President and CMO of $PSNL Sells 100,000 Shares - Quiver Quantitative
Personalis, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain
PSNL Stock Climbs As Morgan Stanley Lifts Price Target - StocksToTrade
$PSNL stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
Personalis (PSNL) Stock Looks Rich Even After A Very Large Run - simplywall.st
PSNL Forecast — Price Target — Prediction for 2027 - TradingView
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data - simplywall.st
Personalis (NASDAQ: PSNL) director receives 6,250 RSU award in Form 4/A update - Stock Titan
Lightspeed funds (NASDAQ: PSNL) report 5.8% Personalis stake after in-kind distributions - Stock Titan
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
EU-certified Personalis blood kits to support global oncology drug trials - Stock Titan
Personalis (NASDAQ: PSNL) CFO sells 40,000 shares under 10b5-1 plan - Stock Titan
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
$PSNL stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
$PSNL stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Ultrasensitive cancer test flags relapses months before scans at ASCO - Stock Titan
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum - Yahoo Finance
Insider Sale: CFO AND COO of $PSNL Sells 38,799 Shares | PSNL Stock News - Quiver Quantitative
Personalis (NASDAQ: PSNL) CEO sells 100K shares after exercising options - Stock Titan
Personalis (PSNL) CFO sells shares via pre-set Rule 10b5-1 plan - Stock Titan
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL) - Seeking Alpha
PSNL - Personalis Inc Stock Price and Quote - Finviz
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis Inc. (PSNL) Surges 7.7% as Precision Medicine Stock Approaches Key Resistance - Gap and Reverse - Město Břeclav
Sector Update: Healthcare Stocks Mixed Late Afternoon
US Agency Broadens Coverage Of Personalis Breast Cancer Test
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis to Participate in Upcoming Investor Events
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Medicare to fund ultrasensitive test showing if cancer immunotherapy works - Stock Titan
Personalis Q1 Earnings Call Highlights